CSRxP Statement on Congressional Hearing to Investigate EpiPen Price Hikes

Sep 22, 2016

CSRxP Statement on Congressional Hearing
to Investigate EpiPen Price Hikes 

The Campaign for Sustainable Rx Pricing (CSRxP) issued the following statement after today’s House Committee on Oversight and Government Reform hearing to investigate rising prices on life-saving EpiPens:

“Today the American people heard how too many pharmaceutical companies have fundamentally failed patients and families,” said CSRxP’s executive director John Rother. “The consequences of unaccountable price increases for EpiPens are felt every day by millions of families across the country. Sadly, this is just the latest example of drug companies trying to justify their skyrocketing price increases. Until we fix the broken prescription drug market with open and honest information, real competition, speeding medicines to the market, and understanding how different medications compare in value, drug prices will continue to put an unsustainable financial burden on patients, families, and the economy.”

Prescription drug companies institute major price hikes on products across the board and EpiPens are just one example of many. Check out the Campaign’s new fact sheet for more information.